```
 => File .Biotech
=> s (polypeptide# or peptide# or therapeut? peptide or polypeptide)
L1      1697755 (POLYPEPTIDE# OR PEPTIDE# OR THERAPEUT? PEPTIDE OR POLYPEPTIDE)

=> s l1 and (glutamic acid or aspartic acid or alanine or asparagine or glutamine
or glycine)
   6 FILES SEARCHED...
L2       166239 L1 AND (GLUTAMIC ACID OR ASPARTIC ACID OR ALANINE OR ASPARAGINE
                OR GLUTAMINE OR GLYCINE)

=> s l2 and (drug cariier)
L3            0 L2 AND (DRUG CARIIER)

=> s l2 and (drug carier)
L4            0 L2 AND (DRUG CARIER)

=> s l2 and (carrier)
L5        39614 L2 AND (CARRIER)

=> s l5 and (drug)
L6        24549 L5 AND (DRUG)

=> s l6 and (metal complex?)
L7         2071 L6 AND (METAL COMPLEX?)

=> s l7 and (conjugat? or combin? or join? or link? (5a)covalent?)
L8         2070 L7 AND (CONJUGAT? OR COMBIN? OR JOIN? OR LINK? (5A) COVALENT?)

=> s l8 and (metal drug)
L9            7 L8 AND (METAL DRUG)

=> d l9 1-7 bib ab

L9   ANSWER 1 OF 7  USPATFULL on STN
AN     2003:176406  USPATFULL
TI     Pharmaceutical preparations of glutathione and methods of administration
       thereof
IN     Demopolos, Harry B., Scarsdale, NY, United States
       Seligman, Myron L., Pleasantville, NY, United States
PA     Antioxidant Pharmaceuticals Corp., Elsmsford, NY, United States (U.S.
       corporation)
PI     US 6586404          B1   20030701
AI     US 2002-200852           20020722 (10)
RLI    Continuation of Ser. No. US 2001-813247, filed on 19 Mar 2001, now
       patented, Pat. No. US 6423687 Continuation of Ser. No. US 1997-2100,
       filed on 31 Dec 1997, now patented, Pat. No. US 6159500 Continuation of
       Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US
       6204248
PRAI   US 1996-34101P      19961231 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Reamer, James H.
LREP   Milde & Hoffberg LLP
CLMN   Number of Claims: 33
ECL    Exemplary Claim: 1,20
DRWN   2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3836
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A method for the administration of glutathione orally comprising the
       administration of a bolus of glutathione which is pharmaceutically
       stabilized and encapsulated. The glutathione is administered on an empty
       stomach. The preferred stabilizer is ascorbic acid.

L9   ANSWER 2 OF 7  USPATFULL on STN
```

AN 2003:159817 USPATFULL
TI Anticancer **polypeptide-metal complexes** and compositions, methods of making, and methods of using same
IN Zuo, William W., Sugar Land, TX, UNITED STATES
Yu, Dongfang, Houston, TX, UNITED STATES
Yang, David J., Sugar Land, TX, UNITED STATES
Xu, Jing Ya, Missouri City, TX, UNITED STATES
PI US 2003109432 A1 20030612
AI US 2001-940180 A1 20011210 (9)
DT Utility
FS APPLICATION
LREP J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428, Bellaire, TX, 77402-2428
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a therapeutic metal selected from the group consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium or rhodium. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

L9 ANSWER 3 OF 7 USPATFULL on STN
AN 2002:250825 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, UNITED STATES
Seligman, Myron L., Pleasantville, NY, UNITED STATES
PI US 2002136763 A1 20020926
AI US 2002-83327 A1 20020225 (10)
RLI A 371 of International Ser. No. WO 1997-US23879, filed on 31 Dec 1997, UNKNOWN Continuation-in-part of Ser. No. US 1999-331947, filed on 28 Jun 1999, GRANTED, Pat. No. US 6350467
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS APPLICATION
LREP Steven M. Hoffberg, MILDE & HOFFBERG, LLP, SUITE 460, 10 BANK STREET, WHITE PLAINS, NY, 10606
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

L9 ANSWER 4 OF 7 USPATFULL on STN
AN 2002:181670 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopolos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)

PI US 6423687 B1 20020723
AI US 2001-813247 20010319 (9)
RLI Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US 6204248 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now patented, Pat. No. US 6159500
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Reamer, James H.
LREP Milde & Hoffberg, LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

L9 ANSWER 5 OF 7 USPATFULL on STN
AN 2002:39674 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6350467 B1 20020226
WO 9829101 19980709
AI US 1999-331947 19990628 (9)
WO 1997-US23879 19971231
19990628 PCT 371 date
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

L9 ANSWER 6 OF 7 USPATFULL on STN
AN 2001:40462 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Fairfield, CT, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6204248 B1 20010320
AI US 1999-457642 19991209 (9)
RLI Continuation of Ser. No. US 331947 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now abandoned
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.

LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 5144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of altering an expression of a gene product in cells or an organism, comprising orally administering glutathione in an effective amount and under such conditions to alter a redox potential in the cells. The gene expression may be sensitive to redox potential through one or more of a process of induction, transcription, translation, post-translational modification, release, and/or through a receptor mediated process. The glutathione is preferably administered as an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach.

L9 ANSWER 7 OF 7 USPATFULL on STN
AN 2000:167548 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corporation, Elmsford, NY, United States (U.S. corporation)
PI US 6159500 20001212
AI US 1997-2100 19971231 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Spear, James M.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

=> s l8 and (transition? metal drug)
L10 1 L8 AND (TRANSITION? METAL DRUG)

=> d l10 bib ab

L10 ANSWER 1 OF 1 USPATFULL on STN
AN 2003:159817 USPATFULL
TI Anticancer **polypeptide-metal complexes** and compositions, methods of making, and methods of using same
IN Zuo, William W., Sugar Land, TX, UNITED STATES
Yu, Dongfang, Houston, TX, UNITED STATES
Yang, David J., Sugar Land, TX, UNITED STATES
Xu, Jing Ya, Missouri City, TX, UNITED STATES
PI US 2003109432 A1 20030612
AI US 2001-940180 A1 20011210 (9)
DT Utility
FS APPLICATION
LREP J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428, Bellaire, TX, 77402-2428
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a therapeutic metal selected from the group consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium or rhodium. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

=> s l8 and (metal complex?)
L11 2070 L8 AND (METAL COMPLEX?)

=> s l11 and (platinum or iron or gadolinium or rhenium or manganese or cobolt or indium or gallium or rhodium)
L12 647 L11 AND (PLATINUM OR IRON OR GADOLINIUM OR RHENIUM OR MANGANESE OR COBOLT OR INDIUM OR GALLIUM OR RHODIUM)

=> s l12 and (therapeutic metal)
L13 8 L12 AND (THERAPEUTIC METAL)

=> d l13 1-8 bib ab

L13 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:173371 CAPLUS
DN 138:226718
TI Compositions containing anticancer **polypeptide-metal complexes**
IN Zuo, William W.; Xu, Jing Ya
PA Fannin Bioscience, Inc., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003017923	A2	20030306	WO 2002-US21624	20020709
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003109432	A1	20030612	US 2001-940180	20011210
PRAI	US 2001-940180	A	20011210		

AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a **therapeutic metal** selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making the complexes, compns. comprising the complexes, methods for making such compns., and methods for treating a patient with these complexes are also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate.

Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated with the poly(amino acid) prepd. above to give a complex. This complex was evaluated in 4 tumor-bearing animal models. The **platinum peptide** complexes are all effective in vivo against breast cancer.

L13 ANSWER 2 OF 8 USPATFULL on STN
AN 2003:159817 USPATFULL
TI Anticancer **polypeptide-metal complexes** and compositions, methods of making, and methods of using same
IN Zuo, William W., Sugar Land, TX, UNITED STATES
Yu, Dongfang, Houston, TX, UNITED STATES
Yang, David J., Sugar Land, TX, UNITED STATES
Xu, Jing Ya, Missouri City, TX, UNITED STATES
PI US 2003109432 A1 20030612
AI US 2001-940180 A1 20011210 (9)
DT Utility
FS APPLICATION
LREP J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428, Bellaire, TX, 77402-2428
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a **therapeutic metal** selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

L13 ANSWER 3 OF 8 USPATFULL on STN
AN 2001:231038 USPATFULL
TI Structurally determined cyclic metallo-constructs and applications
IN Sharma, Shubh D., Plainsboro, NJ, United States
PA Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 6331285 B1 20011218
AI US 1999-464358 19991215 (9)
RLI Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, Dameron L.
LREP Slusher, Stephen A.Peacock, Myers & Adams
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or **combinatorial** chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L13 ANSWER 4 OF 8 USPATFULL on STN
AN 2000:109372 USPATFULL
TI In vivo agents comprising cationic drugs, **peptides** and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
IN Ranney, David F., Dallas, TX, United States
PA Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6106866 20000822
AI US 1995-509338 19950731 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Woodward, Michael P.
LREP Arnold, White & Durkee
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 72 Drawing Page(s)
LN.CNT 3913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A **drug carrier** composition comprising a **drug** complexed with dermatan sulfate is disclosed. The **drug** is preferably an anti tumor **drug** and may be taxol, a **peptide** onco-agent or vincristine. The most preferred antitumor **drug** is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9% (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induces the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the **drug** (diagnostic) **carrier**; 2) sequestration of the **carrier** and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the **carrier** still invaginates into the vascular compartment; 3) acceleration of the **carrier**'s transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (interstitium); and 4) improvement of the efficiency with which the **drug** migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total **drug** dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel.

L13 ANSWER 5 OF 8 USPATFULL on STN
AN 2000:21206 USPATFULL
TI Structurally determined metallo-constructs and applications
IN Sharma, Shubh D., Albuquerque, NM, United States
PA RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)
PI US 6027711 20000222
AI US 1996-660697 19960605 (8)

RLI Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Jones, Dameron
LREP Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or **combinatorial** chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L13 ANSWER 6 OF 8 USPATFULL on STN
AN 1998:138472 USPATFULL
TI Dendrimeric compounds
IN Margerum, Larry, Wayne, PA, United States
Campion, Brian, Solano Beach, CA, United States
Fellmann, Jere Douglas, Livermore, CA, United States
Garrity, Martha, San Clemente, CA, United States
PA Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
PI US 5834020 19981110
WO 9528966 19951102
AI US 1997-722082 19970121 (8)
WO 1995-GB898 19950420
19970121 PCT 371 date
19970121 PCT 102(e) date
PRAI GB 1994-7812 19940420
DT Utility
FS Granted
EXNAM Primary Examiner: Levy, Neil S.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2049
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

L13 ANSWER 7 OF 8 USPATFULL on STN
AN 93:93543 USPATFULL
TI Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
IN Ranney, David F., 3539 Courtdale Dr., Dallas, TX, United States 75234
PI US 5260050 19931109
AI US 1990-463692 19900111 (7)
DCD 20100525
RLI Continuation-in-part of Ser. No. US 1988-252565, filed on 29 Sep 1988, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hollrah, Glennon H.; Assistant Examiner: Hollinden, Gary E.
LREP Arnold, White Durkee
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved compositions and methods for selective access to tumor regions (or other regions of abnormal endothelial properties). This capability provides powerful contrast-enhancement agents for nuclear magnetic resonance imaging. A polyatomic complex which includes intramolecular ferromagnetic coupling between metal atoms is associated with a polymer or microsphere **carrier** matrix which will bind to endothelial determinants. A solution containing this **carrier** complex is injected into a human (or other) body to be imaged. The **carrier** complex will preferentially extravasate at locations where the blood vessel walls have increased porosity or microvascular surface changes, and especially at tumor sites. Thus, the changes in relaxation time induced by the presence of the **carrier** complex will provide a high-gain marker for magnetic resonance imaging.

Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core.

L13 ANSWER 8 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2003-363003 [34] WPIDS
DNC C2003-095754
TI **Glutamic acid** containing **polypeptide-metal complexes**, useful for treating patients afflicted with conditions e.g. cancer.
DC B04 B05
IN XU, J Y; YANG, D J; YU, D; ZUO, W W
PA (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; (FANN-N) FANNIN BIOSCIENCE INC
CYC 97
PI WO 2003017923 A2 20030306 (200334)* EN 78p
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
US 2003109432 A1 20030612 (200340)
ADT WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 20010827
PRAI US 2001-940180 20010827
AB WO2003017923 A UPAB: 20030529
NOVELTY - A therapeutic compound comprises at least one **drug** moiety **covalently linked** to at least one **polypeptide drug carrier** moiety (comprising 50 to 90% **glutamic acid** and 10 to 50% of **aspartic**

acid, **alanine**, **asparagine**, **glutamine** and/or **glycine**).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) a method for making the therapeutic compound;
(2) compositions comprising the therapeutic compound;
(3) a method for making the composition;
(4) a method for treating a patient comprising administration of the compound.

ACTIVITY - Cytostatic.

Cis-1,2-diaminocyclohexane **platinum**(II)-poly(glutamic/**aspartic acid**) (Ia) at 45 mg/kg reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control treated with saline showed tumor growth over 6 days to 16000 mm3.

MECHANISM OF ACTION - None given.

USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic, leukemia, lymphoma, sarcoma, head and neck, lung or liver).

ADVANTAGE - The compounds have improved solubility of the therapeutic agent.

Dwg.0/7

```
=> s l12 and (polypeptide platnium complex)
L14           0 L12 AND (POLYPEPTIDE PLATNIUM COMPLEX)

=> s l12 and (platnium complex?)
L15           0 L12 AND (PLATNIUM COMPLEX?)

=> s l12 and (platnium)
L16           0 L12 AND (PLATNIUM)

=> s l12 and (polyglutamate asparatate or polyglutamate alanine)
L17           0 L12 AND (POLYGLUTAMATE ASPARATATE OR POLYGLUTAMATE ALANINE)

=> s l12 and (diaminocyclohexane platinum II or diaminocyclohexane dichloro
platinum IV)
L18           2 L12 AND (DIAMINOCYCLOHEXANE PLATINUM II OR DIAMINOCYCLOHEXANE
                DICHLORO PLATINUM IV)

=> d l18 1-2 bib ab

L18  ANSWER 1 OF 2  USPATFULL on STN
AN     2003:159817  USPATFULL
TI     Anticancer polypeptide-metal complexes and
       compositions, methods of making, and methods of using same
IN     Zuo, William W., Sugar Land, TX, UNITED STATES
       Yu, Dongfang, Houston, TX, UNITED STATES
       Yang, David J., Sugar Land, TX, UNITED STATES
       Xu, Jing Ya, Missouri City, TX, UNITED STATES
PI     US 2003109432      A1   20030612
AI     US 2001-940180     A1   20011210 (9)
DT     Utility
FS     APPLICATION
LREP   J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428,
       Bellaire, TX, 77402-2428
CLMN   Number of Claims: 54
ECL    Exemplary Claim: 1
DRWN   10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Novel drug complexes comprising a polypeptide
       carrier moiety comprising glutamic acid and
       at least one of the group consisting of aspartic acid
       , alanine, asparagine, glutamine,
       glycine, and any combinations thereof, are disclosed.
```

The **drug** moiety is a therapeutic metal selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

L18 ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2003-363003 [34] WPIDS
DNC C2003-095754
TI **Glutamic acid** containing **polypeptide-metal complexes**, useful for treating patients afflicted with conditions e.g. cancer.
DC B04 B05
IN XU, J Y; YANG, D J; YU, D; ZUO, W W
PA (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; (FANN-N) FANNIN BIOSCIENCE INC
CYC 97
PI WO 2003017923 A2 20030306 (200334)* EN 78p
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
US 2003109432 A1 20030612 (200340)
ADT WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 20010827
PRAI US 2001-940180 20010827
AB WO2003017923 A UPAB: 20030529
NOVELTY - A therapeutic compound comprises at least one **drug** moiety **covalently linked** to at least one **polypeptide drug carrier** moiety (comprising 50 to 90% **glutamic acid** and 10 to 50% of **aspartic acid**, **alanine**, **asparagine**, **glutamine** and/or **glycine**).
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) a method for making the therapeutic compound;
(2) compositions comprising the therapeutic compound;
(3) a method for making the composition;
(4) a method for treating a patient comprising administration of the compound.
ACTIVITY - Cytostatic.
Cis-1,2-**diaminocyclohexane platinum**(II)-poly(glutamic/**aspartic acid**) (Ia) at 45 mg/kg reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control treated with saline showed tumor growth over 6 days to 16000 mm3.
MECHANISM OF ACTION - None given.
USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic, leukemia, lymphoma, sarcoma, head and neck, lung or liver).
ADVANTAGE - The compounds have improved solubility of the therapeutic agent.
Dwg.0/7

```
=> s l12 and (platinum complex?)
L19           9 L12 AND (PLATINUM COMPLEX?)

=> d l19 1-9 b ib ab
'B' IS NOT A VALID FORMAT
'IB' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files.  Refer to file specific help messages
```

or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):d l19 1-9 bib ab
'D' IS NOT A VALID FORMAT
'L152' IS NOT A VALID FORMAT
'1-9' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):bib ab

L19 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:173371 CAPLUS
DN 138:226718
TI Compositions containing anticancer **polypeptide-metal complexes**
IN Zuo, William W.; Xu, Jing Ya
PA Fannin Bioscience, Inc., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003017923	A2	20030306	WO 2002-US21624	20020709
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003109432	A1	20030612	US 2001-940180	20011210
PRAI	US 2001-940180	A	20011210		

AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a therapeutic metal selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making the complexes, compns. comprising the complexes, methods for making such compns., and methods for treating a patient with these complexes are also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate. Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated with the poly(amino acid) prepd. above to give a complex. This complex was evaluated in 4 tumor-bearing animal models. The **platinum peptide** complexes are all effective in vivo against breast cancer.

L19 ANSWER 2 OF 9 USPATFULL on STN
AN 2003:203373 USPATFULL
TI Electronic methods for the detection of analytes utilizing monolayers
IN Yu, Changjun, Pasadena, CA, United States
PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6600026 B1 20030729
AI US 1999-306653 19990506 (9)
RLI Continuation of Ser. No. US 1998-135183, filed on 17 Aug 1998

PRAI US 1998-84652P 19980506 (60)
US 1998-84509P 19980506 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Silva, Robin M., Kosslak, Renee M., Dorsey & Whitney, LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 93 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 4573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of self-assembled monolayers with mixtures of conductive oligomers and insulators to detect target analytes.

L19 ANSWER 3 OF 9 USPATFULL on STN
AN 2003:159817 USPATFULL
TI Anticancer **polypeptide-metal complexes** and compositions, methods of making, and methods of using same
IN Zuo, William W., Sugar Land, TX, UNITED STATES
Yu, Dongfang, Houston, TX, UNITED STATES
Yang, David J., Sugar Land, TX, UNITED STATES
Xu, Jing Ya, Missouri City, TX, UNITED STATES
PI US 2003109432 A1 20030612
AI US 2001-940180 A1 20011210 (9)
DT Utility
FS APPLICATION
LREP J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428, Bellaire, TX, 77402-2428
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a therapeutic metal selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

L19 ANSWER 4 OF 9 USPATFULL on STN
AN 2002:322479 USPATFULL
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI US 2002182643 A1 20021205
AI US 2001-981636 A1 20011016 (9)
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L19 ANSWER 5 OF 9 USPATFULL on STN
AN 2001:157679 USPATFULL
TI Systems for electrophoretic transport and detection of analytes
IN Kayyem, Jon Faiz, Pasadena, CA, United States
Blackburn, Gary, Glendora, CA, United States
O'Connor, Stephen D., Pasadena, CA, United States
PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6290839 B1 20010918
AI US 1998-134058 19980814 (9)
PRAI US 1998-90389P 19980623 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex
LREP Flehr Hohbach Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., Silva, Esq., Robin M.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 44 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 4594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions and methods useful in the electrophoretic transport of target analytes to a detection electrode comprising a self-assembled monolayer (SAM). Detection proceeds through the use of an electron transfer moiety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM.

L19 ANSWER 6 OF 9 USPATFULL on STN
AN 2001:116434 USPATFULL
TI Binding acceleration techniques for the detection of analytes
IN Blackburn, Gary, Glendora, CA, United States
Creager, Stephen E., Central, SC, United States
Fraser, Scott, La Canada, CA, United States
Irvine, Bruce D., Glendora, CA, United States
Meade, Thomas J., Altadena, CA, United States
O'Connor, Stephen D., Pasadena, CA, United States
Terbrueggen, Robert H., Manhattan Beach, CA, United States
Vielmetter, Jost G., Pasadena, CA, United States
Welch, Thomas W., Pasadena, CA, United States
PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6264825 B1 20010724
AI US 1999-338726 19990623 (9)
RLI Continuation of Ser. No. US 1998-134058, filed on 14 Aug 1998
PRAI US 1998-90389P 19980623 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex
LREP Flehr Hohabch Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., Silva, Esq., Robin M.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 49 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 5644
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions and methods useful in the acceleration of binding of target analytes to capture ligands on surfaces. Detection proceeds through the use of an electron transfer moiety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM.

L19 ANSWER 7 OF 9 USPATFULL on STN
AN 2000:142401 USPATFULL
TI Methods of treatment for viral infections
IN Camden, James Berger, West Chester, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6136835 20001024
AI US 1999-394382 19990910 (9)
RLI Continuation-in-part of Ser. No. US 1999-312948, filed on 17 May 1999
DT Utility
FS Granted
EXNAM Primary Examiner: Goldberg, Jerome D.
LREP Rose and Dabek, Rasser, Jacobus C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the treatment of cancers or tumors in mammals are disclosed which uses 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof. A chemotherapeutic agent and/or a potentiator may be used in **combination** with 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof. 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof may also be used to treat viral infections, either alone, in **combination** with other anti-viral agents, or in **combination** with a potentiator.

L19 ANSWER 8 OF 9 USPATFULL on STN
AN 1998:161989 USPATFULL
TI Biologically compatible linear block copolymers of polyalkylene oxide and **peptide** units
IN Cooper, Eugene R., Berwyn, PA, United States
Jones, Stephen P., Morpeth, United Kingdom
Pouton, Colin W., Bristol, United Kingdom
Threadgill, Michael D., Bath, United Kingdom
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5853713 19981229
AI US 1997-790854 19970203 (8)
RLI Division of Ser. No. US 1994-203106, filed on 28 Feb 1994, now patented, Pat. No. US 5618528
DT Utility
FS Granted
EXNAM Primary Examiner: Webman, Edward J.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A linear block copolymer comprising units of an alkylene oxide, linked to units of **peptide** via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, **drug**, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

L19 ANSWER 9 OF 9 USPATFULL on STN
AN 97:29194 USPATFULL
TI Biologically compatible linear block copolymers of polyalkylene oxide

and **peptide** units
IN Cooper, Eugene R., Berwyn, PA, United States
Jones, Stephen P., Morpeth, United Kingdom
Pouton, Colin W., Bristol, United Kingdom
Threadgill, Michael D., Bath, United Kingdom
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5618528 19970408
AI US 1994-203106 19940228 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Webman, Edward J.
LREP Fish & Richardson PC
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A linear block copolymer comprising units of an alkylene oxide, linked to units of **peptide** via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, **drug**, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

=> s l12 and l9 or l13 or l18 or l19
L20 21 L12 AND L9 OR L13 OR L18 OR L19

=> s Zuo William/au
L21 0 ZUO WILLIAM/AU

=> s Zuo, W?/au
L22 289 ZUO, W?/AU

=> s Yu, D?/au
L23 6679 YU, D?/AU

=> s Yang, D?/au
L24 10664 YANG, D?/AU

=> s Xu Jing, Y?/au
L25 37 XU JING, Y?/AU

=> s l20 and l22 or l23 or l24 or l25
L26 17277 L20 AND L22 OR L23 OR L24 OR L25

=> s l26 and (polypeptide metal complex)
L27 3 L26 AND (POLYPEPTIDE METAL COMPLEX)

=> d l27 1-3 bib ab

L27 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:173371 CAPLUS
DN 138:226718
TI Compositions containing anticancer **polypeptide-metal complexes**
IN **Zuo, William W.; Xu, Jing Ya**
PA Fannin Bioscience, Inc., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003017923	A2	20030306	WO 2002-US21624	20020709

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003109432 A1 20030612 US 2001-940180 20011210

PRAI US 2001-940180 A 20011210

AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a **therapeutic metal** selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making the complexes, compns. comprising the complexes, methods for making such compns., and methods for treating a patient with these complexes are also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate. Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated with the poly(amino acid) prepd. above to give a complex. This complex was evaluated in 4 tumor-bearing animal models. The **platinum peptide** complexes are all effective in vivo against breast cancer.

L27 ANSWER 2 OF 3 USPATFULL on STN

AN 2003:159817 USPATFULL

TI Anticancer **polypeptide-metal complexes** and compositions, methods of making, and methods of using same

IN **Zuo, William W.**, Sugar Land, TX, UNITED STATES
Yu, Dongfang, Houston, TX, UNITED STATES
Yang, David J., Sugar Land, TX, UNITED STATES
Xu, Jing Ya, Missouri City, TX, UNITED STATES

PI US 2003109432 A1 20030612

AI US 2001-940180 A1 20011210 (9)

DT Utility

FS APPLICATION

LREP J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428, Bellaire, TX, 77402-2428

CLMN Number of Claims: 54

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 1053

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid** , **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a **therapeutic metal** selected from the group consisting of **platinum**, **iron** , **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

L27 ANSWER 3 OF 3 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2003-363003 [34] WPIDS

DNC C2003-095754

TI **Glutamic acid** containing **polypeptide-metal complexes**, useful for treating patients afflicted with conditions e.g. cancer.

DC B04 B05

IN XU, J Y; **YANG, D J; YU, D; ZUO, W W**

PA (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; (FANN-N) FANNIN BIOSCIENCE INC

CYC 97

PI WO 2003017923 A2 20030306 (200334)* EN 78p
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
US 2003109432 A1 20030612 (200340)

ADT WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 20010827

PRAI US 2001-940180 20010827

AB WO2003017923 A UPAB: 20030529
NOVELTY - A therapeutic compound comprises at least one **drug** moiety **covalently linked** to at least one **polypeptide drug carrier** moiety (comprising 50 to 90% **glutamic acid** and 10 to 50% of **aspartic acid**, **alanine**, **asparagine**, **glutamine** and/or **glycine**).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) a method for making the therapeutic compound;
(2) compositions comprising the therapeutic compound;
(3) a method for making the composition;
(4) a method for treating a patient comprising administration of the compound.

ACTIVITY - Cytostatic.

Cis-1,2-**diaminocyclohexane platinum(II**)-poly(glutamic/**aspartic acid**) (Ia) at 45 mg/kg reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control treated with saline showed tumor growth over 6 days to 16000 mm3.

MECHANISM OF ACTION - None given.

USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic, leukemia, lymphoma, sarcoma, head and neck, lung or liver).

ADVANTAGE - The compounds have improved solubility of the therapeutic agent.

Dwg.0/7

=> d his

(FILE 'HOME' ENTERED AT 16:01:55 ON 26 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
ENTERED AT 16:02:05 ON 26 SEP 2003

```
L1      1697755 S (POLYPEPTIDE# OR PEPTIDE# OR THERAPEUT? PEPTIDE OR POLYPEPTID
L2       166239 S L1 AND (GLUTAMIC ACID OR ASPARTIC ACID OR ALANINE OR ASPARAGI
L3            0 S L2 AND (DRUG CARIIER)
L4            0 S L2 AND (DRUG CARIER)
L5        39614 S L2 AND (CARRIER)
L6        24549 S L5 AND (DRUG)
L7         2071 S L6 AND (METAL COMPLEX?)
L8         2070 S L7 AND (CONJUGAT? OR COMBIN? OR JOIN? OR LINK? (5A)COVALENT?
L9            7 S L8 AND (METAL DRUG)
L10           1 S L8 AND (TRANSITION? METAL DRUG)
L11        2070 S L8 AND (METAL COMPLEX?)
L12         647 S L11 AND (PLATINUM OR IRON OR GADOLINIUM OR RHENIUM OR MANGANE
L13           8 S L12 AND (THERAPEUTIC METAL)
```

```
L14           0 S L12 AND (POLYPEPTIDE PLATNIUM COMPLEX)
L15           0 S L12 AND (PLATNIUM COMPLEX?)
L16           0 S L12 AND (PLATNIUM)
L17           0 S L12 AND (POLYGLUTAMATE ASPARATATE OR POLYGLUTAMATE ALANINE)
L18           2 S L12 AND (DIAMINOCYCLOHEXANE PLATINUM II OR DIAMINOCYCLOHEXANE
L19           9 S L12 AND (PLATINUM COMPLEX?)
L20          21 S L12 AND L9 OR L13 OR L18 OR L19
L21           0 S ZUO WILLIAM/AU
L22         289 S ZUO, W?/AU
L23        6679 S YU, D?/AU
L24       10664 S YANG, D?/AU
L25          37 S XU JING, Y?/AU
L26       17277 S L20 AND L22 OR L23 OR L24 OR L25
L27           3 S L26 AND (POLYPEPTIDE METAL COMPLEX)

=> d l20 1-21 bib ab

L20  ANSWER 1 OF 21  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:173371  CAPLUS
DN   138:226718
TI   Compositions containing anticancer polypeptide-metal
     complexes
IN   Zuo, William W.; Xu, Jing Ya
PA   Fannin Bioscience, Inc., USA
SO   PCT Int. Appl., 78 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2003017923      A2   20030306       WO 2002-US21624  20020709
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2003109432      A1   20030612       US 2001-940180   20011210
PRAI US 2001-940180     A    20011210
AB   Novel drug complexes comprising a polypeptide
     carrier moiety comprising glutamic acid and at
     least one of the group consisting of aspartic acid,
     alanine, asparagine, glutamine,
     glycine, and any combinations thereof, are disclosed.
     The drug moiety is a therapeutic metal
     selected from the group consisting of platinum, iron,
     gadolinium, rhenium, manganese, cobalt,
     indium, gallium or rhodium. Methods for
     making the complexes, compns. comprising the complexes, methods for making
     such compns., and methods for treating a patient with these complexes are
     also disclosed. Thus, polyaspartate-polyglutamate complex was prepd. by
     the reaction of .beta.-benzyl L-aspartate with .gamma.-benzyl L-glutamate.
     Cis-1,2-diaminocyclohexane sulfatoplatinum (II) was prepd. and treated
     with the poly(amino acid) prepd. above to give a complex. This complex
     was evaluated in 4 tumor-bearing animal models. The platinum
     peptide complexes are all effective in vivo against breast cancer.

L20  ANSWER 2 OF 21  USPATFULL on STN
AN     2003:203373  USPATFULL
TI     Electronic methods for the detection of analytes utilizing monolayers
IN     Yu, Changjun, Pasadena, CA, United States
```

PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6600026 B1 20030729
AI US 1999-306653 19990506 (9)
RLI Continuation of Ser. No. US 1998-135183, filed on 17 Aug 1998
PRAI US 1998-84652P 19980506 (60)
US 1998-84509P 19980506 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Silva, Robin M., Kosslak, Renee M., Dorsey & Whitney, LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 93 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 4573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of self-assembled monolayers with mixtures of conductive oligomers and insulators to detect target analytes.

L20 ANSWER 3 OF 21 USPATFULL on STN
AN 2003:176406 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopolos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elsmsford, NY, United States (U.S. corporation)
PI US 6586404 B1 20030701
AI US 2002-200852 20020722 (10)
RLI Continuation of Ser. No. US 2001-813247, filed on 19 Mar 2001, now patented, Pat. No. US 6423687 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now patented, Pat. No. US 6159500 Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US 6204248
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Reamer, James H.
LREP Milde & Hoffberg LLP
CLMN Number of Claims: 33
ECL Exemplary Claim: 1,20
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3836
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

L20 ANSWER 4 OF 21 USPATFULL on STN
AN 2003:159817 USPATFULL
TI Anticancer **polypeptide-metal complexes** and compositions, methods of making, and methods of using same
IN Zuo, William W., Sugar Land, TX, UNITED STATES
Yu, Dongfang, Houston, TX, UNITED STATES
Yang, David J., Sugar Land, TX, UNITED STATES
Xu, Jing Ya, Missouri City, TX, UNITED STATES
PI US 2003109432 A1 20030612
AI US 2001-940180 A1 20011210 (9)
DT Utility
FS APPLICATION
LREP J. M. (Mark) Gilbreth, GILBRETH & ASSOCIATES, P.C., P.O. Box 2428, Bellaire, TX, 77402-2428
CLMN Number of Claims: 54

ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel **drug** complexes comprising a **polypeptide carrier** moiety comprising **glutamic acid** and at least one of the group consisting of **aspartic acid**, **alanine**, **asparagine**, **glutamine**, **glycine**, and any **combinations** thereof, are disclosed. The **drug** moiety is a **therapeutic metal** selected from the group consisting of **platinum**, **iron**, **gadolinium**, **rhenium**, **manganese**, cobalt, **indium**, **gallium** or **rhodium**. Methods for making said complexes, compositions comprising said complexes, methods for making saiduch compositions, and methods for treating a patient comprising use of said complexes and/or compositions are further disclosed.

L20 ANSWER 5 OF 21 USPATFULL on STN
AN 2002:322479 USPATFULL
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI US 2002182643 A1 20021205
AI US 2001-981636 A1 20011016 (9)
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L20 ANSWER 6 OF 21 USPATFULL on STN
AN 2002:250825 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, UNITED STATES
Seligman, Myron L., Pleasantville, NY, UNITED STATES
PI US 2002136763 A1 20020926
AI US 2002-83327 A1 20020225 (10)
RLI A 371 of International Ser. No. WO 1997-US23879, filed on 31 Dec 1997, UNKNOWN Continuation-in-part of Ser. No. US 1999-331947, filed on 28 Jun 1999, GRANTED, Pat. No. US 6350467
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS APPLICATION
LREP Steven M. Hoffberg, MILDE & HOFFBERG, LLP, SUITE 460, 10 BANK STREET, WHITE PLAINS, NY, 10606
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2416

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

L20 ANSWER 7 OF 21 USPATFULL on STN
AN 2002:181670 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopolos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6423687 B1 20020723
AI US 2001-813247 20010319 (9)
RLI Continuation of Ser. No. US 1999-457642, filed on 9 Dec 1999, now patented, Pat. No. US 6204248 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now patented, Pat. No. US 6159500
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Reamer, James H.
LREP Milde & Hoffberg, LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 3706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

L20 ANSWER 8 OF 21 USPATFULL on STN
AN 2002:39674 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6350467 B1 20020226
WO 9829101 19980709
AI US 1999-331947 19990628 (9)
WO 1997-US23879 19971231
19990628 PCT 371 date
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

L20 ANSWER 9 OF 21 USPATFULL on STN

AN 2001:231038 USPATFULL
TI Structurally determined cyclic metallo-constructs and applications
IN Sharma, Shubh D., Plainsboro, NJ, United States
PA Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 6331285 B1 20011218
AI US 1999-464358 19991215 (9)
RLI Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, Dameron L.
LREP Slusher, Stephen A.Peacock, Myers & Adams
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or **combinatorial** chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L20 ANSWER 10 OF 21 USPATFULL on STN
AN 2001:157679 USPATFULL
TI Systems for electrophoretic transport and detection of analytes
IN Kayyem, Jon Faiz, Pasadena, CA, United States
Blackburn, Gary, Glendora, CA, United States
O'Connor, Stephen D., Pasadena, CA, United States
PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6290839 B1 20010918
AI US 1998-134058 19980814 (9)
PRAI US 1998-90389P 19980623 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex
LREP Flehr Hohbach Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., Silva, Esq., Robin M.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 44 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 4594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions and methods useful in the electrophoretic transport of target analytes to a detection electrode comprising a self-assembled monolayer (SAM). Detection proceeds through

the use of an electron transfer moiety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM.

L20 ANSWER 11 OF 21 USPATFULL on STN
AN 2001:116434 USPATFULL
TI Binding acceleration techniques for the detection of analytes
IN Blackburn, Gary, Glendora, CA, United States
Creager, Stephen E., Central, SC, United States
Fraser, Scott, La Canada, CA, United States
Irvine, Bruce D., Glendora, CA, United States
Meade, Thomas J., Altadena, CA, United States
O'Connor, Stephen D., Pasadena, CA, United States
Terbrueggen, Robert H., Manhattan Beach, CA, United States
Vielmetter, Jost G., Pasadena, CA, United States
Welch, Thomas W., Pasadena, CA, United States
PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6264825 B1 20010724
AI US 1999-338726 19990623 (9)
RLI Continuation of Ser. No. US 1998-134058, filed on 14 Aug 1998
PRAI US 1998-90389P 19980623 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tung, T.; Assistant Examiner: Noguerola, Alex
LREP Flehr Hohabch Test Albritton & Herbert LLP, Trecartin, Esq., Richard F., Silva, Esq., Robin M.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 49 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 5644
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions and methods useful in the acceleration of binding of target analytes to capture ligands on surfaces. Detection proceeds through the use of an electron transfer moiety (ETM) that is associated with the target analyte, either directly or indirectly, to allow electronic detection of the ETM.

L20 ANSWER 12 OF 21 USPATFULL on STN
AN 2001:40462 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Fairfield, CT, United States
PA Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S. corporation)
PI US 6204248 B1 20010320
AI US 1999-457642 19991209 (9)
RLI Continuation of Ser. No. US 331947 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now abandoned
PRAI US 1996-34101P 19961231 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 5144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of altering an expression of a gene product in cells or an organism, comprising orally administering glutathione in an effective amount and under such conditions to alter a redox potential in the cells. The gene expression may be sensitive to redox potential through one or more of a process of induction, transcription, translation,

post-translational modification, release, and/or through a receptor mediated process. The glutathione is preferably administered as an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach.

L20 ANSWER 13 OF 21 USPATFULL on STN
AN 2000:167548 USPATFULL
TI Pharmaceutical preparations of glutathione and methods of administration thereof
IN Demopoulos, Harry B., Scarsdale, NY, United States
Seligman, Myron L., Pleasantville, NY, United States
PA Antioxidant Pharmaceuticals Corporation, Elmsford, NY, United States (U.S. corporation)
PI US 6159500 20001212
AI US 1997-2100 19971231 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Spear, James M.
LREP Milde, Hoffberg & Macklin, LLP
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.

L20 ANSWER 14 OF 21 USPATFULL on STN
AN 2000:142401 USPATFULL
TI Methods of treatment for viral infections
IN Camden, James Berger, West Chester, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6136835 20001024
AI US 1999-394382 19990910 (9)
RLI Continuation-in-part of Ser. No. US 1999-312948, filed on 17 May 1999
DT Utility
FS Granted
EXNAM Primary Examiner: Goldberg, Jerome D.
LREP Rose and Dabek, Rasser, Jacobus C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the treatment of cancers or tumors in mammals are disclosed which uses 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof. A chemotherapeutic agent and/or a potentiator may be used in **combination** with 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof. 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol or derivatives thereof may also be used to treat viral infections, either alone, in **combination** with other anti-viral agents, or in **combination** with a potentiator.

L20 ANSWER 15 OF 21 USPATFULL on STN
AN 2000:109372 USPATFULL
TI In vivo agents comprising cationic drugs, **peptides** and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
IN Ranney, David F., Dallas, TX, United States
PA Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S.

corporation)
PI US 6106866 20000822
AI US 1995-509338 19950731 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Woodward, Michael P.
LREP Arnold, White & Durkee
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 72 Drawing Page(s)
LN.CNT 3913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A **drug carrier** composition comprising a **drug** complexed with dermatan sulfate is disclosed. The **drug** is preferably an anti tumor **drug** and may be taxol, a **peptide** onco-agent or vincristine. The most preferred antitumor **drug** is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9% (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induces the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the **drug** (diagnostic) **carrier**; 2) sequestration of the **carrier** and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the **carrier** still invaginates into the vascular compartment; 3) acceleration of the **carrier**'s transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (interstitium); and 4) improvement of the efficiency with which the **drug** migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total **drug** dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel.

L20 ANSWER 16 OF 21 USPATFULL on STN
AN 2000:21206 USPATFULL
TI Structurally determined metallo-constructs and applications
IN Sharma, Shubh D., Albuquerque, NM, United States
PA RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)
PI US 6027711 20000222
AI US 1996-660697 19960605 (8)
RLI Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Jones, Dameron
LREP Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or **combinatorial** chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X,

resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L20 ANSWER 17 OF 21 USPATFULL on STN
AN 1998:161989 USPATFULL
TI Biologically compatible linear block copolymers of polyalkylene oxide and **peptide** units
IN Cooper, Eugene R., Berwyn, PA, United States
Jones, Stephen P., Morpeth, United Kingdom
Pouton, Colin W., Bristol, United Kingdom
Threadgill, Michael D., Bath, United Kingdom
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5853713 19981229
AI US 1997-790854 19970203 (8)
RLI Division of Ser. No. US 1994-203106, filed on 28 Feb 1994, now patented, Pat. No. US 5618528
DT Utility
FS Granted
EXNAM Primary Examiner: Webman, Edward J.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A linear block copolymer comprising units of an alkylene oxide, linked to units of **peptide** via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, **drug**, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

L20 ANSWER 18 OF 21 USPATFULL on STN
AN 1998:138472 USPATFULL
TI Dendrimeric compounds
IN Margerum, Larry, Wayne, PA, United States
Campion, Brian, Solano Beach, CA, United States
Fellmann, Jere Douglas, Livermore, CA, United States
Garrity, Martha, San Clemente, CA, United States
PA Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
PI US 5834020 19981110
WO 9528966 19951102
AI US 1997-722082 19970121 (8)
WO 1995-GB898 19950420
19970121 PCT 371 date
19970121 PCT 102(e) date
PRAI GB 1994-7812 19940420
DT Utility
FS Granted
EXNAM Primary Examiner: Levy, Neil S.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2049
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or

therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

L20 ANSWER 19 OF 21 USPATFULL on STN
AN 97:29194 USPATFULL
TI Biologically compatible linear block copolymers of polyalkylene oxide and **peptide** units
IN Cooper, Eugene R., Berwyn, PA, United States
Jones, Stephen P., Morpeth, United Kingdom
Pouton, Colin W., Bristol, United Kingdom
Threadgill, Michael D., Bath, United Kingdom
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5618528 19970408
AI US 1994-203106 19940228 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Webman, Edward J.
LREP Fish & Richardson PC
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A linear block copolymer comprising units of an alkylene oxide, linked to units of **peptide** via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, **drug**, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

L20 ANSWER 20 OF 21 USPATFULL on STN
AN 93:93543 USPATFULL
TI Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
IN Ranney, David F., 3539 Courtdale Dr., Dallas, TX, United States 75234
PI US 5260050 19931109
AI US 1990-463692 19900111 (7)
DCD 20100525
RLI Continuation-in-part of Ser. No. US 1988-252565, filed on 29 Sep 1988, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hollrah, Glennon H.; Assistant Examiner: Hollinden, Gary E.
LREP Arnold, White Durkee
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved compositions and methods for selective access to tumor regions (or other regions of abnormal endothelial properties). This capability provides powerful contrast-enhancement agents for nuclear magnetic resonance imaging. A polyatomic complex which includes intramolecular ferromagnetic coupling between metal atoms is associated with a polymer or microsphere **carrier** matrix which will bind to endothelial determinants. A solution containing this **carrier** complex is injected into a human (or other) body to be imaged. The **carrier** complex will preferentially extravasate at locations where the blood vessel walls have increased porosity or microvascular surface changes, and especially at tumor sites. Thus, the changes in relaxation time induced by the presence of the **carrier** complex will provide a high-gain marker for magnetic resonance imaging.

Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core.

L20 ANSWER 21 OF 21 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2003-363003 [34] WPIDS
DNC C2003-095754
TI **Glutamic acid** containing **polypeptide-metal complexes**, useful for treating patients afflicted with conditions e.g. cancer.
DC B04 B05
IN XU, J Y; YANG, D J; YU, D; ZUO, W W
PA (XUJY-I) XU J Y; (YANG-I) YANG D J; (YUDD-I) YU D; (ZUOW-I) ZUO W W; (FANN-N) FANNIN BIOSCIENCE INC
CYC 97
PI WO 2003017923 A2 20030306 (200334)* EN 78p
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
US 2003109432 A1 20030612 (200340)
ADT WO 2003017923 A2 WO 2002-US21624 20020709; US 2003109432 A1 US 2001-940180 20010827
PRAI US 2001-940180 20010827
AB WO2003017923 A UPAB: 20030529
NOVELTY - A therapeutic compound comprises at least one **drug** moiety **covalently linked** to at least one **polypeptide drug carrier** moiety (comprising 50 to 90% **glutamic acid** and 10 to 50% of **aspartic acid**, **alanine**, **asparagine**, **glutamine** and/or **glycine**).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) a method for making the therapeutic compound;
(2) compositions comprising the therapeutic compound;
(3) a method for making the composition;
(4) a method for treating a patient comprising administration of the compound.

ACTIVITY - Cytostatic.
Cis-1,2-**diaminocyclohexane platinum**(II)-poly(glutamic/**aspartic acid**) (Ia) at 45 mg/kg reduced a breast tumor volume from 4000 mm3 to zero over 6 days. A control treated with saline showed tumor growth over 6 days to 16000 mm3.

MECHANISM OF ACTION - None given.

USE - The compounds are useful for treating patients afflicted with a condition (claimed) especially cancer (prostate, breast, ovarian, colonic, leukemia, lymphoma, sarcoma, head and neck, lung or liver).

ADVANTAGE - The compounds have improved solubility of the therapeutic agent.

Dwg.0/7

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:39:50 ON 26 SEP 2003